Common Contracts

EX-10.17 2 dex1017.htm ASSIGNMENT AND PURCHASE AGREEMENT ASSIGNMENT AND PURCHASE AGREEMENT

Assignment and Purchase Agreement • May 5th, 2020 • California

• Contract Type
  Assignment and Purchase Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  California

THIS ASSIGNMENT AND PURCHASE AGREEMENT (the “Agreement”) is entered into this 25th day of April, 2007 (the “Effective Date”) by and among Resistys, Inc., a Delaware corporation having its principal place of business at 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (“Resistys”), Avantogen Limited (formerly, Australian Cancer Technology Limited), an Australian corporation having its principal place of business at 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (“Avantogen”), Avantogen Oncology, Inc. (formerly, Innovate Oncology, Inc.), a Nevada corporation having its principal place of business at 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (“AOI”), and SciClone Pharmaceuticals, Inc. a Delaware corporation, having its principal place of business at 901 Mariners Island Blvd., San Mateo, California 94404 (“Buyer”) (Resistys, Avantogen and AOI also referred to herein individually and collectively as, “Seller”).

ASSIGNMENT AND PURCHASE AGREEMENT

Assignment and Purchase Agreement • October 3rd, 2007 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations • California

• Contract Type
  Assignment and Purchase Agreement
• Filed
  October 3rd, 2007
• Company
  Sciclone Pharmaceuticals Inc
• Industry
  Pharmaceutical preparations
• Jurisdiction
  California

THIS ASSIGNMENT AND PURCHASE AGREEMENT (the “Agreement”) is entered into this 25th day of April, 2007 (the “Effective Date”) by and among Resistys, Inc., a Delaware corporation having its principal place of business at 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (“Resistys”), Avantogen Limited (formerly, Australian Cancer Technology Limited), an Australian corporation having its principal place of business at 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (“Avantogen”), Avantogen Oncology, Inc. (formerly, Innovate Oncology, Inc.), a Nevada corporation having its principal place of business at 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (“AOI”), and SciClone Pharmaceuticals, Inc. a Delaware corporation, having its principal place of business at 901 Mariners Island Blvd., San Mateo, California 94404 (“Buyer”) (Resistys, Avantogen and AOI also referred to herein individually and collectively as, “Seller”).